Comparative Pharmacology
Head-to-head clinical analysis: CISATRACURIUM BESYLATE PRESERVATIVE FREE versus TUBOCURARINE CHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CISATRACURIUM BESYLATE PRESERVATIVE FREE versus TUBOCURARINE CHLORIDE.
CISATRACURIUM BESYLATE PRESERVATIVE FREE vs TUBOCURARINE CHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, blocking acetylcholine binding and preventing muscle contraction.
Competitive antagonist at nicotinic acetylcholine receptors (nAChRs) at the neuromuscular junction, blocking ACh binding and preventing depolarization, resulting in skeletal muscle paralysis.
Initial bolus: 0.15-0.2 mg/kg IV; maintenance infusion: 1-3 mcg/kg/min IV titrated to desired neuromuscular blockade.
0.1-0.2 mg/kg intravenous bolus for initial intubation; maintenance: 0.05-0.1 mg/kg every 20-40 minutes as needed for neuromuscular blockade.
None Documented
None Documented
Terminal elimination half-life is approximately 22-29 minutes in patients with normal renal and hepatic function. Clinical context: Recovery of neuromuscular function is predictable and independent of organ function due to Hofmann elimination.
Terminal elimination half-life: 1.3–2.9 hours in adults with normal renal function. In renal failure, half-life is prolonged (up to 6–10 hours). Clinically, this leads to prolonged neuromuscular blockade in patients with renal impairment.
Renal (77%) and fecal (11%) as unchanged drug. Minor hepatic metabolism via Hofmann elimination (non-enzymatic) and ester hydrolysis. No active metabolites.
Primarily renal excretion (approximately 70-80% unchanged in urine via glomerular filtration). A minor fraction (10-20%) is excreted in bile into feces. Less than 1% is metabolized (deacetylation to less active desmethyl derivatives).
Category C
Category C
Neuromuscular Blocker (Nondepolarizing)
Neuromuscular Blocker (Nondepolarizing)